Syneos HealthUnclaimed
Host of The Syneos Health Podcast: Early Signals.
1 Feed-stated
Counts Verified and Feed-stated credits: what a show's own feed states, or a confirmation backs. See the record
- Host
Claim this profile Add a creditIs this you? Claiming needs a free account. You sign in or join, then come straight back here.
This profile is unclaimed. PodSubs built it from public show feeds and credits. The person it is about has not reviewed it yet.
PodCred record
PodCred is the verified record of where Syneos has worked and appeared. These credits come from the shows' own feeds and wait for people who were there to confirm them.
Worked with Syneos on a show? This is where you give them credit.
Shows they work on now
1 show
Is an appearance missing?
People get invited back because someone remembered they were great. If you heard this person on a show and it is not listed here, add it. Your memory might be the reason they get their next invitation.
No account needed. Anyone can give a credit.
Experience, education, skills, and recommendations start empty. They fill in when Syneos claims this profile.
Recommendations
No recommendations for Syneos yet.
Recommendations open once Syneos claims the profile.
Posts
No posts yet. Posts Syneos shares on PodSubs, and what Syneos publishes on Substack, YouTube and elsewhere, will show here.
Recent episodes
From the shows they work on now
Can We Redefine Cancer by Its Biology?
The Syneos Health Podcast: Early Signals
What if the future of oncology is defined not by where a tumor originates, but by the molecular biology driving it? In this episode of Early Signals, recorded at ASCO 2026, Wael Harb, MD, MBA, sits down with precision...
Early Signals at ASCO 2026 | Can Real-World Evidence Bring Research Closer to Patients?
The Syneos Health Podcast: Early Signals
Can real-world evidence do more than support regulatory decisions? Could it fundamentally change how clinical research is designed, delivered and connected to patient care? In this episode of The Syneos Health Podcast:...
Early Signals at ASCO 2026 | Beyond Digitization: How AI Is Transforming Clinical Trial Operations
The Syneos Health Podcast: Early Signals
If clinical trials are already digitized, why do clinical operations remain so complex, manual and resource-intensive? In this episode of Early Signals, Wael Harb, MD, speaks with Ram Yalamanchili, Founder and CEO of...
Early Signals at ASCO 2026 | Can TIL Therapy Reach More Patients?
The Syneos Health Podcast: Early Signals
Can the next generation of tumor-infiltrating lymphocyte (TIL) therapies overcome the barriers that have limited broader adoption of cell therapy in solid tumors? In this episode of Early Signals, recorded live at ASCO...
Early Signals at ASCO 2026 | Is MRD Ready to Guide Drug Development?
The Syneos Health Podcast: Early Signals
Can minimal residual disease (MRD) do more than measure response? Could it redefine how multiple myeloma therapies are developed, approved and ultimately used to guide patient care? In this episode of Early Signals,...
Early Signals at ASCO 2026 | Can AI Predict Cancer's Next Move? Rethinking Drug Resistance in Oncology
The Syneos Health Podcast: Early Signals
Can AI predict cancer's next move before drug resistance develops? Drug resistance remains one of the greatest challenges in oncology drug development. Most targeted therapies are designed to treat today's tumor...
Early Signals at ASCO 2026 | AI, Multimodal Data and the Next Era of Precision Oncology
The Syneos Health Podcast: Early Signals
What if artificial intelligence could help remove the uncertainty from cancer treatment decisions? Precision oncology has already transformed cancer care by matching therapies to actionable biomarkers, but today's...
Early Signals at ASCO 2026 | Can AI Finally Rebuild Clinical Research?
The Syneos Health Podcast: Early Signals
Less than 5% of patients participate in clinical trials today; a statistic that has remained virtually unchanged for more than two decades despite massive advances in science and technology. In this episode of Early...
Early Signals at ASCO 2026 | How Do You Turn Next-Generation ADC Science Into Global Clinical Success?
The Syneos Health Podcast: Early Signals
Antibody-drug conjugates (ADCs) are transforming oncology, but scientific innovation alone isn't enough. As platforms become more sophisticated - with novel linker technologies, diversified payloads and increasingly...
Early Signals at ASCO 2026 | Reigniting Response: How Oncolytic Viruses May Reshape Ovarian Cancer Treatment
The Syneos Health Podcast: Early Signals
What happens when an established treatment regains its effectiveness against resistant disease? In this episode of the Syneos Health Podcast: Early Signals, Wael Harb, MD, Head of R&D and Scientific Strategy in Oncology...
